MedTrace Logo

Toxin Retrospective Study

NCT03042052 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 292

Last updated 2017-02-03

No results posted yet for this study

Summary

Aims of this study were to assess the long-term outcomes of detrusor injection of OnabotulinumtoxinA (Botox® injection) associated with clean intermittent-catheterization (CIC) for the treatment of neurogenic detrusor overactivity (NDO) and to identify risk factors for failure.

Conditions

  • Neurogenic Bladder

Interventions

DRUG

detrusor infection of Botulinum toxin

detrusor injection

Sponsors & Collaborators

  • Centre d'Investigation Clinique et Technologique 805

    lead OTHER

Principal Investigators

  • EVEN Alexia, MD · HOPITAL RAYMOND POINCARE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-01
Primary Completion
2016-05-01
Completion
2016-06-01
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03042052 on ClinicalTrials.gov